Phase II evaluation of Ly156758 in metastatic breast cancer.
about
Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cellsRaloxifene: handle with careEffect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancerEffect of SERMs on breast tissue.Effect of Red Clover on CYP Expression: An Investigation of Herb-Drug Interaction at Molecular Level.Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancerSelective estrogen receptor modulators: tissue specificity and clinical utility.Tamoxifen: a most unlikely pioneering medicine.The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer.From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs).From adjuvant therapy to breast cancer prevention: BCPT and STAR.Arzoxifene: the evidence for its development in the management of breast cancer.Effects of tamoxifen versus raloxifene on retinal capillary endothelial cell proliferationBeyond raloxifene for the prevention of osteoporosis and breast cancerBF3·Et2O Catalysed 4-Aryl-3-phenyl-benzopyrones, Pro-SERMs, and Their Characterization.Arzoxifene: the development and clinical outcome of an ideal SERM.Raloxifene and the prevention of breast cancer.Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer.Selective estrogen receptor modulators and phytoestrogens.Endocrine therapy for the treatment of postmenopausal women with breast cancer.Raloxifene hydrochloride for breast cancer risk reduction in postmenopausal women.Raloxifene: a selective estrogen-receptor modulator for postmenopausal osteoporosis - a clinical update on efficacy and safety.Chemoprevention with antiestrogens: the beginning of the end for breast cancer. Daniel G. Miller Lecture.First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.Effects of high dose raloxifene in selected patients with advanced breast carcinoma.New Hormonal Therapies for Breast Cancer.Chemoprevention of breast cancer
P2860
Q28343990-59D0C042-CAFC-4906-BCAB-184A141086FBQ28345935-F0B486F0-6A29-4A1D-8969-66A1E1EC3AC7Q28366565-363A1776-2D9D-4C64-BF1E-D46AD3C2C37BQ33757750-4CCD10BE-A356-48B6-82FE-B1EC063BE32AQ33877807-1FE0A2F9-5535-42FF-B273-5CD8391EF371Q34110074-A00081FB-D5EB-49C6-931E-AB8620538685Q34134828-EBFFED50-14B0-4DD8-A5E1-0E7E67E23A2CQ34180688-5123AA93-16AF-42BB-AC41-081A1C6D5F93Q34311300-2B5308D4-0C73-4B41-B8A8-53CB659B28FFQ34315413-E4AF6A6F-F841-4B9D-95A4-9E2E8680448EQ34317586-7318D5C6-6E1B-40A6-B445-F0F5100E80A4Q34449901-E84A8BE9-6193-4494-980B-814A1FBE9C98Q35024239-4926F105-155C-4A05-8E06-E658E8AD33C2Q36052490-BCEF5DB3-4FDA-4AE9-BCDB-3A34AEC7B903Q36059489-2F5A7250-A180-44F0-9576-B875BF45D20DQ36407322-4AFB3492-1AAA-4637-9C3A-407DD6345D66Q36632266-FC518253-5C53-4C31-9EB2-938EA3CBD670Q36684234-53F1E67A-A61D-4F5B-95DF-46729F0A7219Q36927087-8CFC0946-3637-4836-A033-6F634CE7F96CQ36984515-7B17C686-AA25-41E9-9266-1C311C8146E0Q37385376-F7091FE0-B9CF-492A-9F85-7D40DE5401CDQ38825454-2F743697-9EAB-448F-8974-B88F26BD9E05Q43267067-D2D49DF5-9384-4B4C-BF33-8EE155EB648EQ43857245-8C80199C-A2BC-4184-985D-52DA2AF3BFADQ47884041-E94BE7E3-D0A4-406D-AF28-D924DF31498AQ53521747-386224D0-B680-4C59-A65E-722DADDA9812Q54056103-9EB09F89-502F-42A1-A3D6-8997DC85BB3DQ57133081-E1376652-7825-4EF4-807E-15CB91994AFB
P2860
Phase II evaluation of Ly156758 in metastatic breast cancer.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年学术文章
@wuu
1988年学术文章
@zh-cn
1988年学术文章
@zh-hans
1988年学术文章
@zh-my
1988年学术文章
@zh-sg
1988年學術文章
@yue
1988年學術文章
@zh
1988年學術文章
@zh-hant
name
Phase II evaluation of Ly156758 in metastatic breast cancer.
@en
Phase II evaluation of Ly156758 in metastatic breast cancer.
@nl
type
label
Phase II evaluation of Ly156758 in metastatic breast cancer.
@en
Phase II evaluation of Ly156758 in metastatic breast cancer.
@nl
prefLabel
Phase II evaluation of Ly156758 in metastatic breast cancer.
@en
Phase II evaluation of Ly156758 in metastatic breast cancer.
@nl
P2093
P356
P1433
P1476
Phase II evaluation of Ly156758 in metastatic breast cancer.
@en
P2093
P304
P356
10.1159/000226637
P577
1988-01-01T00:00:00Z